A 78-Year Old Urothelial Cancer Patient with Faster Recovery from COVID-19: Potential Benefit from Adjuvant Active Immunotherapy
21 Pages Posted: 4 Jun 2020
Date Written: May 24, 2020
A 78-year old male patient under active immunotherapy for high-grade non-muscle invasive bladder cancer presented severe COVID-19. A shorter hospitalization period was observed, leading to the hypothesis of active immunotherapy (OncoTherad) crucial role in association to antiviral and anti-inflammatory treatment in preventing the evolution of pulmonary symptoms to a poor prognosis.
Note: Funding: This work was supported by São Paulo Research Foundation (FAPESP) [2019/05718-3 to J.D. and 2018/10052-1 to W.J.F].
Conflict of Interest: The authors declare no competing interests.
Ethical Approval: This study was approved by the ethics committee at UNICAMP.
Keywords: COVID-19, SARS-CoV-2, Immunotherapy, OncoTherad, Metabolomics
JEL Classification: I1
Suggested Citation: Suggested Citation